Nasdaq GlobeNewswire

LifeSci Advisors Expands Presence Into Europe

Del

NEW YORK, 2015-11-17 14:00 CET (GLOBE NEWSWIRE) -- LifeSci Advisors, LLC, (the "Company" or "LifeSci") an investor relations and corporate communications firm focused on the life sciences sector, today announced the appointment of Chris Maggos as Managing Director, Europe and the expansion of the Company's services to European clientele.

Mr. Maggos has over 20 years of experience in the life sciences industry covering business development, investor relations, public relations, journalism, and molecular biology. He is the founder of BioConfidant Sàrl, a Geneva-based strategic consulting firm that helped senior executives achieve their financing and partnering goals. Previously, while at Addex Therapeutics (SWX:ADXN), he was a member of the executive management board and held the positions of Head of Investor Relations & Communication from 2007 to 2010 and Director of Business Development from 2010 to 2013. Prior to Addex Therapeutics, Mr. Maggos was a journalist for BioCentury, a leading biotechnology trade publication, from 2001 to 2007. He began his career in the life sciences as a molecular biologist studying drug dependence at The Rockefeller University from 1993 to 1997, where he co-authored 12 peer-reviewed publications. He is also the co-Founder of the Alpine Institute for Drug Discovery, a not-for-profit social enterprise whose mission is to help commercialize academic discoveries. Mr. Maggos holds a BA in English Literature from Yale University, where he also completed pre-medical studies.

"Chris has an exceptional ability to help life sciences companies translate their value proposition to both the investment and scientific communities," said Andrew McDonald, Chief Executive Officer at LifeSci Advisors. "We have seen an increasing number of European companies seek introductions to the U.S. capital markets. With this hire, we look forward to expanding our presence in the region and serving as a valuable partner to those companies as they continue to develop their products and seek new sources of funding."

About LifeSci Advisors, LLC

LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With local presence in New York, Boston, Chicago, and Geneva, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of Ph.D.s enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of financial services, investor relations, and public relations specialists help our clients effectively communicate their strategies to the marketplace. This combination of life sciences, financial services, and investor relations expertise allows us to provide a valuable and unique service offering to our clients.

Visit our website:

www.lifesciadvisors.com

         CONTACT: For further information, please contact:
         
         Andrew I. McDonald Ph.D.
         Chief Executive Officer
         Tel.: (646) 597-6987
         
         Michael Rice
         President
         Tel.: (646) 597-6979

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

David Crosby Announces Intent to License His Name to the Cannabis Industry18.7.2018 18:04Pressemelding

Music industry icon pursuing licensing partnership with a leading Cannabis company LOS ANGELES and TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- David Crosby, co-founder of two of the most successful bands in history (Crosby, Stills, Nash & Young, and The Byrds) today announced he is seeking a licensing relationship with a national or global Cannabis company. This opportunity would include the exclusive license of his iconic name and marks for use worldwide. Mr. Crosby suggests calling the brand "MIGHTY CROZ" because his friends, colleagues and fans call him "Croz", but specific naming and packaging will be determined in consultation with the selected Cannabis company. Mr. Crosby will actively advise the selected Cannabis company in developing and marketing the brand. "People have been asking me to do a quality Cannabis brand and with legalization expanding, now is the right time," said David Crosby from his ranch in California. "Our first priority is partnering with a leading Cannabis co

Telecom Argentina's landing station and backhaul are selected for ARBR submarine cable system between Argentina & Brazil18.7.2018 17:00Pressemelding

ARBR + Seabras-1 to provide most direct route between Buenos Aires & New York BUENOS AIRES, Argentina and BOSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Telecom Argentina S.A. ("Telecom Argentina") (BASE:TECO2) (NYSE:TEO), one of Argentina's leading telecommunications companies, Grupo Werthein, a preeminent Argentine investment holding company with a track record of significant telecommunications holdings, and Seaborn Networks ("Seaborn"), a leading developer-owner-operator of submarine fiber optic cable systems, announced today that the ARBR submarine cable system between Argentina and Brazil ("ARBR") will be landing in Telecom Argentina's cable landing station in Las Toninas, Argentina. In addition, Telecom Argentina shall provide ARBR with dark fiber on a backhaul route between Las Toninas and Buenos Aires, as well as point of presence (POP) space in Buenos Aires. ARBR is a new fiber optic submarine cable system developed by Seaborn and co-owned by Seaborn's Seabras Group together with T

Salim Ismail Announced as Keynote Speaker at Mitratech's Interact 2018 Conference18.7.2018 15:02Pressemelding

Best-Selling Author and Tech Strategist Shares Insights on New Paradigm in Organizational Design AUSTIN, Texas, July 18, 2018 (GLOBE NEWSWIRE) -- Mitratech, the leading provider of legal and compliance software solutions, today announced that Salim Ismail, best-selling author, founding executive director of Singularity University, and founder of ExO Works, will deliver the keynote address at its Interact 2018 Conference. Every year the Interact conference provides an opportunity for clients, industry experts and partners to connect, learn, and contribute to insightful sessions on Mitratech innovations, legal operations best practices and industry trends. This year's theme, The Next Frontier of Legal Ops, recognizes that legal operations should be a center of innovation and excellence that brings people, processes and information together like never before by extending legal operations capabilities across the entire enterprise. "Salim understands the power of innovation and technology t

Corvil Introduces AI-Powered "Intelligence Hub" to Help Businesses Achieve Superior Digital Experiences and Performance18.7.2018 15:00Pressemelding

The solution delivers powerful big data analytics insights to business and operational users without the traditional lengthy timelines and costs DUBLIN, Ireland, July 18, 2018 (GLOBE NEWSWIRE) -- Corvil today announced Intelligence Hub, the next generation of digital intelligence to improve the performance, agility and digital experience of today's modern businesses. Intelligence Hub offers the potential to dramatically change how organizations see, manage and optimize their business and supporting technology operations. Today's businesses require a new type of "digital intelligence" that understands and correlates changes in the critical dimensions of business outcomes, user and customer experience, underlying application and infrastructure performance, and cybersecurity. Intelligence Hub provides proactive alerting on changes in these dimensions and allows business and operations teams to flexibly visualize, explore and analyze this key information for more informed action. " Intelli

Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership18.7.2018 14:00Pressemelding

RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership. Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services backed by comprehensive capabilities and cutting-edge, fully-licensed technologies. Custom animal models play a critical role in new drug discovery as biological systems that provide critical insight into the dynamic between a potential therapeutic and a living organism. Combining over twenty years of experience, the industry's most extensive model generation technology portfolio, and seamless integration to downstream premium custom breeding solutions, Taconic is recognized for creating complex genetically engineered mice and rats for biomedical research. Cyagen entered the indu

Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)18.7.2018 13:30Pressemelding

Ongoing Alzheimer's disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer's disease clinical development portfolio including aducanumab, elenbecestat, and BAN2401 Data underscore Biogen's long-term commitment to furthering Alzheimer's disease research and treatment, with a focus on patients with early stage disease CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) announced it will present data from its Alzheimer's disease clinical development portfolio at the upcoming Alzheimer's Association International Conference (AAIC) in Chicago (July 22-26). Data being presented are part of Biogen's research programs targeting several of the identified causes of Alzheimer's disease, focusing on early-stage disease. "The data to be presented at AAIC exemplify our belief that treatments are needed at the earliest stages of Alzheimer's disease to impact the underlying pathophysiology and delay disease p

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom